β-TrCP1 degradation is a novel action mechanism of PI3K/mTOR inhibitors in triple-negative breast cancer cells.

Yi, Yong Weon

β-TrCP1 degradation is a novel action mechanism of PI3K/mTOR inhibitors in triple-negative breast cancer cells. [electronic resource] - Experimental & molecular medicine Feb 2015 - e143 p. digital

Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

2092-6413

10.1038/emm.2014.127 doi


Cell Line, Tumor
Cell Proliferation
Cell Survival--drug effects
Cyclin E--genetics
Dose-Response Relationship, Drug
Female
Furans--pharmacology
Gene Knockdown Techniques
Humans
Mechanistic Target of Rapamycin Complex 2
Models, Biological
Multiprotein Complexes--antagonists & inhibitors
Phosphoinositide-3 Kinase Inhibitors
Phosphorylation--drug effects
Protein Kinase Inhibitors--pharmacology
Proteolysis--drug effects
Proto-Oncogene Proteins c-myc--genetics
Pyridines--pharmacology
Pyrimidines--pharmacology
TOR Serine-Threonine Kinases--antagonists & inhibitors
Triple Negative Breast Neoplasms--genetics
beta-Transducin Repeat-Containing Proteins--genetics